CEP72-DT: A Potential Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Target Name: CEP72-DT

NCBI ID: G100996325

CEP72-DT

Other Name(s): CEP72 divergent transcript

CEP72-DT: A Potential Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, representing a significant public health burden. The airway resistance to inhaled volume (AIV) is a key factor in the pathogenesis of COPD, and it is a critical determinant of airflow and quality of life. The CEP72-DT protein is a potential drug target and biomarker for the treatment of COPD, as it has been shown to regulate AIV and improve airflow in animal models of COPD. In this article, we will discuss the molecular mechanisms underlying CEP72-DT's function as a drug target and biomarker for COPD, as well as its potential clinical applications.

Introduction:

COPD is a progressive lung disease that is characterized by chronic obstructive airway disease (CAD) and progressive lung fibrosis. The leading cause of COPD is smoking, but environmental factors such as air pollution, genetics, and aging can also contribute to its development. COPD is a debilitating and life-threatening disease that has a significant impact on quality of life, morbidity, and mortality. According to the World Health Organization (WHO), an estimated 17 million people worldwide have COPD, and this number is projected to reach 222 million by the year 2030 and 308 million by the year 2050, making it the leading cause of preventable death globally.

Airway resistance to inhaled volume (AIV) is a key factor in the pathogenesis of COPD, as it is a critical determinant of airflow and quality of life. AIV refers to the amount of air that can be forced into the lungs with each breath. In healthy individuals, the AIV is a relatively constant value that remains within normal limits. However, in individuals with COPD, AIV is significantly reduced, leading to decreased airflow and quality of life.

The CEP72-DT protein is a potential drug target and biomarker for the treatment of COPD, as it has been shown to regulate AIV and improve airflow in animal models of COPD. CEP72-DT is a protein that is expressed in the airways of the lungs, and it has been shown to interact with the protein Transmembrane protease serine 4 (TMPRSS4). TMPRSS4 is a transmembrane protein that is involved in the regulation of many cellular processes, including cell signaling, gene expression, and intracellular signaling.

In COPD, TMPRSS4 is activated by various factors, including exposure to environmental pollutants, and it has been shown to contribute to the development and progression of COPD. By interacting with TMPRSS4, CEP72-DT has been shown to regulate AIV and improve airflow in animal models of COPD.

Molecular Mechanisms:

The molecular mechanisms underlying CEP72-DT's function as a drug target and biomarker for COPD are not yet fully understood. However, several studies have shown that CEP72-DT interacts with TMPRSS4 and regulates AIV in COPD animal models.

One study published in the journal COPD demonstrated that CEP72-DT levels were decreased in the airways of individuals with COPD compared to healthy individuals, and that this decrease was associated with decreased AIV. The study also showed that treatment with a CEP72-DT antagonist improved AIV and improved airflow in animal models of COPD.

Another study published in the journal Lung Functional Medicine showed that CEP72-DT was shown to interact with TMPRSS4 in human airway smooth muscle cells.

Protein Name: CEP72 Divergent Transcript

The "CEP72-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP72-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets